The three risk groups reveal that nonthoracic location is associated with a statistically significantly improved prognosis, and nonthoracic NC patients whose tumor has a BRD3-NUTM1 or NSD3-NUTM1 fusion are within the best prognostic group. This evidence concerns the gene NUTM1 and neoplasm.